The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.
Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...
The firm is aiming to break even on its cash flow by 2027 by narrowing its focus on its sarcoma treatments and pipeline candidates with greatest potential.
The firm aims to advance two breast cancer therapies in HR-positive, HER2-negative advanced breast cancer this year.
The OIG recommended that the FDA define factors that would trigger an application's review by an agency council, which the agency disagreed with.